Barclays keeps Keysight at Overweight and lifts price target to $439
Barclays maintained its Overweight rating on Keysight Technologies and raised the price target from $429 to $439, a 2.3% increase, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Barclays kept its Overweight rating on Keysight Technologies and increased its price target by 2.3%, from $429 to $439. According to TradingView, the new target implies upside of 56.0% from the November 19 close of $281.42.
The report also points to historical analyst ratings and notes that Benzinga supplied part of the reference data. The text adds that it is not a personal recommendation and does not constitute investment advice.
why it matters
A single broker's rating change usually affects one stock rather than the broader market. Investors typically focus more on the company's upcoming results and guidance, since an analyst's target reflects an estimate rather than a guaranteed price move.
tags
instruments
sources
- Barclays maintains Keysight Techs at Overweight, raises price target to $439 from $429 — TradingView, 20 November 2026 at 15:09 UTC
- Barclays maintains Medline at Overweight, raises price target to $45 from $43 — TradingView, 20 November 2026 at 15:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗